ArticleDiscover oncology2025
Comparative efficacy of Palbociclib and Everolimus with aromatase inhibitors in second line treatment of HR and HER2 negative metastatic breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) often develops resistance to endocrine therapy (ET), necessitating targeted therapies like Palbociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor). This retrospective cohort study compares their efficacy as second-line therapy combined with aromatase inhibitors in HR+/HER2 − MBC.
methodsIn this retrospective observational cohort study, A cohort of 100 women with HR+/HER2 − MBC was analyzed, with 50 receiving Palbociclib plus an aromatase inhibitor and 50 receiving Everolimus plus an aromatase inhibitor. Propensity score matching balanced baseline characteristics (age, metastatic sites, prior treatments). The primary endpoint, progression-free survival (PFS), and secondary endpoint, overall survival (OS), were assessed using Kaplan-Meier analysis and Cox proportional hazards models. Adverse events were compared using Fisher’s exact test.
resultsMedian PFS was 19 months (95% CI: 16.2–21.8) for Palbociclib versus 11 months (95% CI: 8.7–13.3) for Everolimus (HR: 0.52, 95% CI: 0.32–0.85, P = 0.009). Median OS was 32 months (95% CI: 28.5–35.5) for Palbociclib versus 26 months (95% CI: 22.3–29.7) for Everolimus (HR: 0.68, 95% CI: 0.47–0.99, P = 0.045). Subgroup analyses showed stronger Palbociclib benefits in postmenopausal patients (PFS HR: 0.50, P = 0.008) and those with bone-only metastases (PFS HR: 0.48, P = 0.007). Adverse events included neutropenia (Palbociclib, 70%) and mouth sores (Everolimus, 76%), with comparable severe event rates (P = 0.298).
conclusionOur study suggests that Palbociclib is associated with improved PFS and OS compared to Everolimus in second-line HR+/HER2 − MBC, particularly in postmenopausal and bone-only metastasis subgroups, with manageable toxicity. These findings support Palbociclib’s role in optimizing treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.